Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

497
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
497
Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and prognostic value of blood neurofilament light chain in ischemic stroke: an individual patient data meta-analysis.

Journal of neurology·2026
Same author

RNA-Based Biomarkers for Diagnostic Discrimination of Ischemic and Hemorrhagic Stroke: A Systematic Review.

Journal of clinical medicine·2026
Same author

Molecular insights on the proangiogenic effects of VEGF like growth factor derived from horseshoe crab perivitelline fluid.

Scientific reports·2026
Same author

An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy.

Cell reports·2025
Same author

Blood-based MMP-9 for the early differentiation of acute ischemic stroke: a systematic review and meta-analysis.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2025
Same author

Structure-Guided Stapling of Dimeric Conformations and Linker Engineering Enhance Thermostability and Fine-Tune Activity of Bispecific VHH Cytokine Agonists.

Antibodies (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jun 17, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

690

IL-2 based cancer immunotherapies: an evolving paradigm.

Sushama Rokade1, Anita Mehta Damani1, Martin Oft1

  • 1Development Department, Synthekine, Menlo Park, CA, United States.

Frontiers in Immunology
|August 8, 2024
PubMed
Summary

Interleukin-2 (IL-2) immunotherapy shows promise for cancer treatment but faces limitations. Novel engineering strategies and combination therapies are being developed to improve efficacy and reduce toxicity for better patient outcomes.

Keywords:
IL-2IL-2 receptorsIL-2 toxicitiesIL-2 variantscancer immunotherapycombination therapyoncolytic viruses

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

308

Related Experiment Videos

Last Updated: Jun 17, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

690
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

308

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Interleukin-2 (IL-2) is a critical cytokine for immune regulation, T cell expansion, and tolerance.
  • High-dose IL-2 was an early immunotherapy for renal cell carcinoma and melanoma, with durable responses in some patients.
  • Wild-type IL-2 therapy is limited by short half-life, vascular toxicity, and effects on regulatory and effector T cells.

Purpose of the Study:

  • To review the biological characteristics, efficacy, and toxicities of IL-2 in cancer therapy.
  • To explore novel engineering strategies and combination therapies to enhance IL-2's therapeutic potential.
  • To discuss the development of safer IL-2-based immunotherapies for cancer treatment.

Main Methods:

  • Review of existing literature on IL-2 biology, receptor interactions, and clinical applications.
  • Analysis of preclinical and clinical data on IL-2 efficacy and toxicity in cancer.
  • Exploration of emerging engineering approaches and combination strategies involving IL-2.

Main Results:

  • IL-2 plays a crucial role in immune responses but has clinical limitations in cancer treatment.
  • Engineering strategies and combination therapies (e.g., with PD-1/L1 blockade) show potential to overcome IL-2's toxicity and improve anti-tumor efficacy.
  • Despite challenges, IL-2 remains a focus for developing improved cancer immunotherapies.

Conclusions:

  • Novel IL-2 engineering and combination approaches are crucial for realizing its full therapeutic potential in oncology.
  • Addressing IL-2's toxicity and optimizing its immune-modulating effects are key to developing safer and more effective cancer treatments.
  • Further research into IL-2-based immunotherapies holds promise for improved patient outcomes in various cancers.